What Ipamorelin Medicinal Is
Ipamorelin Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on Ipamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The domain modifier "medicinal" is editorial framing — positioning this site as a medicinal chemistry and pharmacology reference document, not as a claim about services offered. The site presents published research the way a technical digest presents primary literature: findings summarized, doses attributed to species and study, citations numbered and linked. No prescription services are offered. No consultation services are offered. No clinical recommendations are made.
Ipamorelin (NNC 26-0161) is not FDA-approved for any human indication. The compound is a research peptide studied in preclinical rodent models and, in one Phase 2 trial, in post-surgical human patients. The FDA Pharmacy Compounding Advisory Committee voted against adding ipamorelin acetate to the 503A bulk drug substances list in October 2024.[16] Ipamorelin is prohibited under WADA S2 at all times for athletes under WADA-governed sports.[9] This site documents the research record — it does not promote, recommend, or facilitate access to the compound.
Ipamorelin is prohibited at all times under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). No therapeutic use exemption pathway is available under current WADA policy.[9]
Editorial Standards
Every quantitative claim on this site is cited to a numbered reference in the references list. Citations are drawn exclusively from PubMed-indexed publications, ClinicalTrials.gov records, FDA official documents, and peer-reviewed journal sources. No citation is invented; no claim is made without a documented source in the primary literature.
The voice is technical-trust: spare, precise, study-attributed. Findings are stated as findings of the cited study — "Raun et al. 1998 found" or "in rat models at 1–100 µg/kg IV" — not as general truths about the compound. Limitations are stated where the research record states them: ipamorelin's foundational literature is primarily rodent models at relatively small n; human extrapolation requires significant caution; no large-scale longitudinal safety data in humans exists.
No medical advice is dispensed on any page. No dose recommendation for human use is made anywhere on this site. The dosage page documents what was administered to which species at which dose in which study. It is a literature summary, not a protocol.
About the Compound Documented Here
Ipamorelin is a five-amino-acid peptide (pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) synthesized by Novo Nordisk under the designation NNC 26-0161. It was designated "the first selective growth hormone secretagogue" by Raun et al. in 1998,[1] a classification that has remained in the literature since. The compound binds GHS-R1a (the ghrelin receptor) on anterior pituitary somatotrophs to produce discrete, bounded GH pulses without elevating cortisol, ACTH, prolactin, or gonadotropins at studied doses.[1]
PubMed indexes more than 150 publications related to ipamorelin. The majority are preclinical rodent models. Human data is sparse: the most advanced human investigation is the Phase 2 clinical trial for postoperative ileus (NCT00672074), which completed without an NDA submission.[15] This site summarizes the primary research record — not the entirety of the indexed literature, but the findings that constitute the cited evidence base for the compound's main research areas: receptor pharmacology, bone biology, GI motility, body composition, pharmacokinetics, and regulatory status.